Asandeutertinib vs Icotinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
Asandeutertinib
Marketed by TYK Medicines, Inc.
NCT05146219 · Phase 2 · completed
The study treated 29 participants in a single arm without randomization, blinding, or a control group. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2027 · NCT06672068 (registry estimate)
Reported efficacy
Intracranial Overall Response Rate (iORR) (13 months.); Extracranial Overall Response Rate (eORR) (13 months.): Confirmed investigator-assessed intracranial ORR 93.1% (95% CI: 77.2%-99.2%) in 29 patients at 160 mg once daily; median PFS 13.5 months (not_applicable)
Result source: NCT05146219
Icotinib
Marketed by Betta Pharmaceuticals Co.
NCT01040780 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled trial with 200 participants assigned to icotinib and 199 to gefitinib, and its primary endpoint was the clinical measure of progression-free survival. Although the reported median favored icotinib, the statistical significance of the primary comparison is not stated, so the result is unclear rather than definitively positive.
Next expected readout: October 2030 · NCT07458919 (registry estimate)
Reported efficacy
Progression Free Survival (12 months): Primary endpoint, PFS (CONVINCE trial): icotinib 11.2 months vs cisplatin/pemetrexed+pemetrexed maintenance 7.9 months; HR 0.61 (95% CI 0.43-0.87), p=0.006 (met)
Result source: NCT01719536
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Asandeutertinib | Icotinib |
|---|---|---|
| PFS, median | —Trial running · NCT05382728 | 4.6 vs 3.4vs GefitinibNCT010407801 other result
|
| OS, median | —Trial running · NCT05382728 | 13.3 vs 13.9vs GefitinibNCT01040780 |
| ORR | —Trial running · NCT05382728 | —Not posted · NCT04206072 |
| Duration of response, median | —Trial running · NCT05382728 | —Not posted · NCT04206072 |
PFS, median
- Asandeutertinib
- —Trial running · NCT05382728
- Icotinib
- 4.6 vs 3.4vs GefitinibNCT01040780
1 other result
- 11.2 vs 7.9 NCT01719536
OS, median
- Asandeutertinib
- —Trial running · NCT05382728
- Icotinib
- 13.3 vs 13.9vs GefitinibNCT01040780
ORR
- Asandeutertinib
- —Trial running · NCT05382728
- Icotinib
- —Not posted · NCT04206072
Duration of response, median
- Asandeutertinib
- —Trial running · NCT05382728
- Icotinib
- —Not posted · NCT04206072
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Asandeutertinib: 0 of 4 rows · Icotinib: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Icotinib |
|---|---|
| Dropout rate | 0.5%a NCT01040780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 1 more result0% NCT02264210 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT01040780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 1 more result— NCT02264210 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 6.5%a NCT01040780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 1 more result6.3% NCT02264210 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a rash 40.5% diarrhea 21.5% pain 18% NCT01040780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 1 more resultrash 39.7% (placebo 0%) diarrhoea 20.6% (placebo 0%) pain 11.1% (placebo 0%) NCT02264210 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Icotinib
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Asandeutertinib's landscape · Icotinib's landscape